Sean Cao, PhD, MBA

Sean Cao, PhD, MBA

Co-Founder, CEO

Sean is an Operating Partner of CBC Group (formerly C-Bridge Capital) and the CEO of ABio-X holdings, a company created by CBC to focus on company incubation. Sean is also the co-founder and first CEO of Ensem Therapeutics, the co-founder and board director of RVAC Medicines, Jadeite Medicines and Kudo Biotechnology. In 2017, Sean co-founded Everest Medicines, and served as its CEO until 2020. While building Everest Medicines, Sean also incubated NiKang Therapeutics with its scientific co-founders, served as the CEO from 2017 to 2020 and the Chairman until 2021. Sean also served as the CBO for I-Mab Biopharma from the company’s inception in 2016 until early 2018. Prior to CBC, Sean was VP of Global Business Development at Simcere Pharmaceutical Group, and the President and Board Director at Simcere of America. Before joining Simcere, Sean was the Senior Director of Alternative Partnership, Evaluation & Expertise at Sanofi, where he led the externalization effort in Global R&D and managed the evaluation of acquisition/in-licensing opportunities. Prior to Sanofi, Sean was an Associate at New Leaf Venture Partners. Sean had worked in the pharmaceutical and diagnostic industries for over eight years at Aventis and Johnson & Johnson, before joining New Leaf.

Sean holds a PhD in Microbiology from the University of Virginia, an MBA with honor from the Wharton School of the University of Pennsylvania, and a BS in Microbiology from Nankai University, China.